Please provide your email address to receive an email when new articles are posted on . Patients had lower potassium levels and normokalemia within 15 days of potassium treatment. Patients on ...

Potassium binders historically have been used short term or intermittently. Long-term potassium binder use might decrease the risk for adverse outcomes in patients with recurrent hyperkalemia, ...

In 2 small case series of solid-organ transplant recipients, the potassium binders patiromer and sodium zirconium cyclosilicate appeared effective in the short term in managing hyperkalemia. Potassium ...

Hemodialysis was found to be a poor prognostic factor for patients with RCC. The effect of sodium zirconium cyclosilicate is being investigated on arrhythmia-related cardiovascular outcomes in ...

blood test Nearly 74% of hemodialysis patients experienced pre-dialysis hyperkalemia within 1 year of enrollment in the Dialysis Outcomes and Practice Patterns Study, according to investigators. In ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...

Credit: Getty Images. This investigation is among the first observational studies to examine potassium binder use and hard clinical outcomes. Use of the potassium binder patiromer may reduce the risks ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AUSTIN, Texas -- ...

Swedish investigators looked at potassium levels and all-cause mortality in HFrEF patients at 30 days, 12 months, and 5 years. Over all 3 time frames, the sweet spot in terms of lowest hazard risk for ...